NeurologyLive® Mind Moments®

De: NeurologyLive
Escúchala gratis

  • Resumen

  • Mind Moments®, a podcast from NeurologyLive® (https://www.neurologylive.com/) , brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/) .
    Más Menos
activate_WEBCRO358_DT_T2
Episodios
  • 123: Previewing Cleveland Clinic's Epilepsy Summit

    123: Previewing Cleveland Clinic's Epilepsy Summit
    Sep 6 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, epilepsy expert Imad Najm, MD, PhD, sat down to discuss the upcoming Cleveland Clinic Epilepsy Summit, an educational symposium that takes place September 11-15, in Cleveland, Ohio. Najm, who serves as the director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute, spoke about the objectives and goals of the meeting, including updates on sEEG, epilepsy surgery, treatments for drug-resistant epilepsy, and gene therapy. In addition, he provided an overview of the latest advances in epilepsy surgery, genetics, and seizure controlling approaches. Furthermore, he spoke on some of the educational challenges with adjusting to changes in neurosurgery, the potential benefits and limitations of gene therapy, and the future of epilepsy treatment.

    Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

    Episode Breakdown:
    • 1:10 – Mission and goals of Epilepsy Summit
    • 3:05 – Overviewing sessions and educational attainment
    • 4:55 – Changes to epilepsy surgery, advances over the years
    • 9:15 – Neurology News Minute
    • 11:50 – Learning curve for understanding new epilepsy surgery tactics
    • 13:50 – Closing thoughts on the upcoming meeting
    • 15:50 – Potential benefits and challenges to gene therapy for epilepsy

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • EMA Accepts Marketing Authorization Application for Huntington Disease Agent Pridopidine
    • BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 HERCULES Study of Non-Relapsing Secondary Progressive MS
    • FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    23 m
  • 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease

    122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease
    Aug 23 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD). Cohen, who also serves as the medical director of the Toronto Memory Program at the University of Toronto, discussed the potential of RNA therapeutics for treating AD, the unique mechanism of action of mivelsiran, and some of the early promising safety, efficacy, and pharmacokinetic data observed in the phase 1 trial. In addition, Cohen touched upon the idea of how RNA therapeutics could be used in combination with previously approved novel treatments and the benefits mivelsiran brings with no observed amyloid-related imaging abnormalities. Furthermore, the discussion covered some of the potential of this investigational agent, what to expect in the multi-dose part B of the study, and an additional phase 2 study in cerebral amyloid angiopathy.


    Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page.

    Episode Breakdown:
    • 1:15 – Mechanism of action of mivelsiran and how it can be potentially beneficial in AD
    • 4:15 – Growing knowledge of RNA therapeutics and their impact on neurologic conditions
    • 7:00 – Neurology News Minute
    • 10:10 – Phase 1 study data, including efficacy, safety, biomarker, and pharmacokinetic results
    • 19:20 – How mivelsiran fits with other approved therapies for AD; future goals and directions of the drug

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis
    • Muscle-Targeting Therapy Apitegromab Effective in Spinal Muscular Atrophy Over 4 Year Period
    • FDA Approves Medtronic’s Deep Brain Stimulation Technology for Asleep Capabilities

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    24 m
  • 121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate

    121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate
    Aug 9 2024
    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Phil Jochelson, therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals, sat down to discuss the phase 4 XYLO study, a randomized controlled study evaluating the effects of switching from high-sodium to low-sodium oxybate on blood pressure in patients with narcolepsy. Jochelson gave some insight regarding the conduct of the trial, including end points, objectives, and patient demographics, as well as some of the benefits to studying blood pressure and cardiovascular risks. In addition, he discussed enhancements to narcolepsy care through low-sodium oxybate, the importance of unique studies like XYLO, and the need to educate clinicians on sodium load and its risks.


    Looking for more sleep disorders discussion? Check out the NeurologyLive® sleep disorders clinical focus page.

    Episode Breakdown:
    • 1:15 – Reasons behind the XYLO study and links between high sodium intake and cardiovascular risk
    • 4:45 – Patient demographics; inclusion and exclusion criterias
    • 6:40 – Neurology News Minute
    • 9:25 – Overview of XYLO and determining what a successful study looks like
    • 15:30 – Improved understanding of the benefits of low-sodium oxybate

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • EU Regulatory Review Adopts Negative Opinion of Lecanemab as Treatment for Alzheimer Disease
    • GLP-1 Agonist Liraglutide Shows Protective Effects on Alzheimer Disease in Phase 2 Trial
    • FDA Approves Carbidopa/Levodopa ER Capsules Formulation IPX203 for Parkinson Disease

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
    21 m
Enfermedades Físicas Hygiene & Healthy Living Ciencia
Más Menos

Lo que los oyentes dicen sobre NeurologyLive® Mind Moments®

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles